|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
|
ATE305507T1
(de)
*
|
1998-05-14 |
2005-10-15 |
Coley Pharm Gmbh |
Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
|
|
EP1102786A4
(en)
*
|
1998-08-03 |
2002-03-06 |
Univ East Carolina |
AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS
|
|
AU5911899A
(en)
*
|
1998-09-09 |
2000-03-27 |
Genzyme Corporation |
Methylation of plasmid vectors
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
US7083796B2
(en)
*
|
2000-06-20 |
2006-08-01 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
|
WO2000062736A2
(en)
*
|
1999-04-06 |
2000-10-26 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
|
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
DK1200580T3
(da)
*
|
1999-08-13 |
2005-04-11 |
Hybridon Inc |
Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
|
|
WO2001024820A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
|
EP1322655B1
(en)
|
2000-01-14 |
2007-11-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
CZ303468B6
(cs)
|
2000-02-23 |
2012-10-03 |
Smithkline Beecham Biologicals S. A. |
Imunogenní smes a farmaceutická smes
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
|
EP2000144A1
(en)
|
2000-05-19 |
2008-12-10 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
|
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
|
AU9475001A
(en)
*
|
2000-09-26 |
2002-04-08 |
Hybridon Inc |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
|
ATE398175T1
(de)
*
|
2000-12-08 |
2008-07-15 |
Coley Pharmaceuticals Gmbh |
Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
CA2451974C
(en)
|
2001-06-21 |
2014-10-14 |
Karen L. Fearon |
Chimeric immunomodulatory compounds and methods of using the same
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
WO2003020884A2
(en)
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
PT1567641E
(pt)
|
2001-08-24 |
2012-08-21 |
Uvic Industry Partnerships Inc |
Proaerolisina contendo sequência de activação de proteases e métodos de uso para o tratamento do cancro da próstata
|
|
IL160809A0
(en)
|
2001-09-20 |
2004-08-31 |
Glaxo Group Ltd |
HIV-gag CODON-OPTIMISED DNA VACCINES
|
|
US7514414B2
(en)
|
2001-09-24 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Suppressors of CpG oligonucleotides and methods of use
|
|
WO2004012669A2
(en)
|
2002-08-01 |
2004-02-12 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
PT1456380E
(pt)
*
|
2001-11-02 |
2012-07-23 |
Giuliani Int Ltd |
Inibidores smad7 para o tratamento de doenças do snc
|
|
CA2860702C
(en)
|
2001-12-17 |
2019-02-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
EP1474432A1
(en)
*
|
2002-02-04 |
2004-11-10 |
Biomira Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
CA2512108C
(en)
|
2003-01-06 |
2013-04-02 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
US7354907B2
(en)
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
|
AU2004226605A1
(en)
*
|
2003-04-02 |
2004-10-14 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
CA2536139A1
(en)
|
2003-09-25 |
2005-04-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
|
GEP20094767B
(en)
*
|
2003-10-30 |
2009-09-10 |
Coley Pharm Group Inc |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
|
CN1989439B
(zh)
|
2004-05-06 |
2010-12-29 |
美国政府健康及人类服务部 |
治疗葡萄膜炎的方法以及组合物
|
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
US9809824B2
(en)
|
2004-12-13 |
2017-11-07 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
EP2386314A1
(en)
|
2005-03-31 |
2011-11-16 |
GlaxoSmithKline Biologicals SA |
Vaccines against chlamydial infection
|
|
EP2426141B1
(en)
|
2005-04-29 |
2014-10-01 |
GlaxoSmithKline Biologicals S.A. |
Method for preventing or treating M tuberculosis infection
|
|
EP1891093B1
(en)
|
2005-06-14 |
2011-03-23 |
Protox Therapeutics Incorporated |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
|
ES2621211T3
(es)
|
2007-04-04 |
2017-07-03 |
Infectious Disease Research Institute |
Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
|
|
US9452209B2
(en)
*
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
|
NZ599777A
(en)
|
2007-11-07 |
2013-09-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
PL2222710T3
(pl)
|
2007-12-24 |
2017-01-31 |
Id Biomedical Corporation Of Quebec |
Rekombinowane antygeny rsv
|
|
WO2009143292A2
(en)
|
2008-05-21 |
2009-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
|
EP2374813A1
(en)
|
2008-12-03 |
2011-10-12 |
Proyecto de Biomedicina Cima, S.L. |
Use of phenol-soluble modulins for vaccine development
|
|
AU2010264686A1
(en)
|
2009-06-24 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
MX2012000035A
(es)
|
2009-06-24 |
2012-02-28 |
Id Biomedical Corp Quebec |
Antigenos de virus de sincicio respiratorio recombinantes.
|
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
DK2707385T3
(da)
|
2011-05-13 |
2017-11-20 |
Glaxosmithkline Biologicals Sa |
RSV-F-præfusionsantigener
|
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
MX385774B
(es)
|
2012-08-03 |
2025-03-18 |
Infectious Disease Res Inst |
Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
WO2014024026A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
FI2970398T3
(fi)
|
2013-03-13 |
2024-08-06 |
Us Health |
Rsv f -prefuusioproteiineja ja niiden käyttö
|
|
UY35418A
(es)
|
2013-03-15 |
2014-10-31 |
Glaxosmithkline Biolog Sa |
Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
|
|
EP2978447B1
(en)
|
2013-03-28 |
2019-05-08 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
AU2014304545A1
(en)
|
2013-08-05 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
|
CN106659777A
(zh)
|
2014-06-13 |
2017-05-10 |
葛兰素史密丝克莱恩生物有限公司 |
免疫原性组合产品
|
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
|
CN113563468A
(zh)
|
2014-12-19 |
2021-10-29 |
雷根尼桑斯公司 |
结合人c6的抗体及其用途
|
|
KR102193635B1
(ko)
|
2015-01-09 |
2020-12-21 |
이투빅스 코포레이션 |
복합 면역요법을 위한 방법 및 조성물
|
|
AU2015384786B2
(en)
|
2015-03-03 |
2020-08-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
WO2016172249A1
(en)
|
2015-04-20 |
2016-10-27 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
MX375989B
(es)
|
2015-05-26 |
2025-03-07 |
Ohio State Innovation Foundation |
Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
KR20190009308A
(ko)
|
2016-05-21 |
2019-01-28 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
|
|
CN109890408A
(zh)
|
2016-05-27 |
2019-06-14 |
埃特彼塞斯公司 |
新表位疫苗组合物及其使用方法
|
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
UA129243C2
(uk)
|
2017-04-19 |
2025-02-26 |
Інстітьют Фо Рісьорч Ін Біомедцін |
Антитіло, що зв'язується зі спорозоїтами p. falciparum
|
|
JP2020524143A
(ja)
|
2017-06-15 |
2020-08-13 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
ナノ構造脂質担体、安定エマルジョン、およびその使用
|
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
|
MX2020004543A
(es)
|
2017-11-03 |
2020-09-18 |
Takeda Vaccines Inc |
Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
|
|
WO2019147925A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
WO2019183570A1
(en)
|
2018-03-22 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
|
|
US11459393B2
(en)
|
2018-04-17 |
2022-10-04 |
Celldex Therapeutics, Inc. |
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
|
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
CA3214853A1
(en)
|
2021-04-09 |
2022-10-13 |
Celidex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
EP4583841A1
(en)
|
2022-09-09 |
2025-07-16 |
Access to Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
|
CN121219315A
(zh)
|
2023-03-03 |
2025-12-26 |
塞德斯医疗公司 |
抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
|